Citigroup Downgrades PAREXEL International Corporation to Neutral

Brokerage firm Citigroup Downgrades its rating on PAREXEL International Corporation(PRXL). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by Citigroup was issued on Feb 3, 2017.

In a different note, On Dec 16, 2016, Goldman Sachs said it Downgrades its rating on PAREXEL International Corporation. The shares have been rated ‘Sell’ by the firm.

PAREXEL International Corporation (PRXL) made into the market gainers list on Tuesdays trading session with the shares advancing 0.37% or 0.23 points. Due to strong positive momentum, the stock ended at $62.63, which is also near the day’s high of $63. The stock began the session at $62.29 and the volume stood at 14,75,883 shares. The 52-week high of the shares is $72.32 and the 52 week low is $51.16. The company has a current market capitalization of $3,336 M and it has 5,32,67,019 shares in outstanding.

PAREXEL International Corporation(PRXL) last announced its earnings results on Feb 1, 2017 for Fiscal Year 2017 and Q2.Company reported revenue of $534.400M. Analysts had an estimated revenue of $537.240M. Earnings per share were $0.85. Analysts had estimated an EPS of $0.84.

Several Insider Transactions has been reported to the SEC. On Aug 16, 2016, Gadi Saarony (Senior Vice President, CRS) sold 2,500 shares at $70.05 per share price.Also, On Aug 10, 2016, Joshua Schultz (SVP, PAREXEL Access) sold 2,500 shares at $68.64 per share price.On Jun 14, 2016, A Dana Jr Callow (director) sold 3,000 shares at $60.04 per share price, according to the Form-4 filing with the securities and exchange commission.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

Share this post

Leave a Reply